OrthoPediatrics (KIDS) Expected to Announce Quarterly Earnings on Tuesday

OrthoPediatrics (NASDAQ:KIDS) will likely be announcing its Q3 2025 results after the market closes on Tuesday, October 28th. Analysts expect OrthoPediatrics to post earnings of ($0.24) per share and revenue of $63.6270 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, October 28, 2025 at 4:30 PM ET.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Monday, January 9th. The company reported ($0.15) EPS for the quarter. The business had revenue of $25.08 million for the quarter. OrthoPediatrics had a negative return on equity of 6.36% and a negative net margin of 18.92%. On average, analysts expect OrthoPediatrics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

OrthoPediatrics Trading Up 2.1%

NASDAQ KIDS opened at $17.61 on Tuesday. The business’s fifty day moving average is $19.30 and its 200-day moving average is $20.71. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.66 and a quick ratio of 3.43. The stock has a market capitalization of $441.48 million, a price-to-earnings ratio of -9.84 and a beta of 1.02. OrthoPediatrics has a one year low of $15.28 and a one year high of $32.00.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on KIDS. Lake Street Capital cut their price target on shares of OrthoPediatrics from $37.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, October 10th. Piper Sandler cut their price target on shares of OrthoPediatrics from $30.00 to $22.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. JMP Securities decreased their target price on OrthoPediatrics from $35.00 to $25.00 and set a “market outperform” rating for the company in a research report on Friday, October 10th. Citigroup reissued an “outperform” rating on shares of OrthoPediatrics in a research report on Friday, October 10th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $26.29.

Insider Buying and Selling at OrthoPediatrics

In related news, CFO Fred Hite purchased 5,076 shares of OrthoPediatrics stock in a transaction dated Thursday, August 21st. The stock was bought at an average cost of $19.41 per share, for a total transaction of $98,525.16. Following the completion of the transaction, the chief financial officer owned 213,065 shares in the company, valued at $4,135,591.65. This trade represents a 2.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 31.80% of the company’s stock.

Hedge Funds Weigh In On OrthoPediatrics

Several hedge funds have recently made changes to their positions in the stock. Sei Investments Co. grew its position in shares of OrthoPediatrics by 27.1% in the second quarter. Sei Investments Co. now owns 38,947 shares of the company’s stock valued at $837,000 after purchasing an additional 8,312 shares in the last quarter. Marshall Wace LLP grew its position in shares of OrthoPediatrics by 17.8% in the second quarter. Marshall Wace LLP now owns 419,129 shares of the company’s stock valued at $9,003,000 after purchasing an additional 63,345 shares in the last quarter. Invesco Ltd. grew its position in shares of OrthoPediatrics by 22.5% in the second quarter. Invesco Ltd. now owns 22,482 shares of the company’s stock valued at $483,000 after purchasing an additional 4,133 shares in the last quarter. American Century Companies Inc. grew its position in shares of OrthoPediatrics by 12.5% in the second quarter. American Century Companies Inc. now owns 34,486 shares of the company’s stock valued at $741,000 after purchasing an additional 3,828 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of OrthoPediatrics in the first quarter valued at $389,000. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.